Both Annamycin dose arms outperformed control on the primary endpoint of complete remission (CR): 43% and 36% versus 12% — ...

Iran had reportedly pressed Buehler about the matter in the immediate aftermath of the La Belle bombing and subsequent ...

A recent study found that a combination of dietary fibers effectively alleviated chronic constipation, enhancing bowel ...

After neoadjuvant therapy, ctDNA clearance occurred in 96% of patients ...

Applied Biologics, a biopharmaceutical company advancing novel biologic therapies for chronic wounds, tissue repair, and degenerative disease, presented interim clinical data from the CAMPX Trial at ...

Data from EULAR 2026 show that next-generation CAR T- and NK cell platforms induce powerful, drug-free clinical remissions in patients with highly refractory rheumatic diseases.

Researchers have found in a pragmatic cluster-randomized quality improvement trial that asynchronous electronic (e-) screening significantly increased both screening completion rates ...

After a four-month investigation, Nature Medicine has decided to pull a viral study that linked early-day PD-1/chemo treatment to a massive survival benefit versus late-day infusion in non-small cell ...

Americans love working from home. Does it love them back? A controversial new study says remote work is taking a toll on ...

Tesamorelin can selectively reduce visceral fat, as demonstrated in RCTs. But the real story is what it reveals about metabolism, peptides, and the future of self-driven health ...

FDA’s PDUFA goal date is November 1, 2026; If approved, mitapivat is positioned to become the first oral PK activator for patients with sickle cell disease; CAMBRIDGE, Mass., Ju ...